†Total adverse events encompasses all intensities. Mild = no interference with daily activities; moderate = interferes with daily activities; severe = daily activities interrupted.*Subjects with multi
Background PD-1/PD-L1 inhibitors (PI) have shown promising results in both neoadjuvant and adjuvant therapies for resectable non-small cell lung cancer (NSCLC). However, substantial evidence from larg